Nonetheless, the clinical translatability of these observations is limited by the heterogeneous expression of EGFR in breast cancer and the common emergence of resistance, underscoring the need for robust predictive biomarkers and more advanced preclinical models. The gene discussed is EGFR; the disease is breast cancer.